1 Control Print Ltd (NSE: CONTROLPR): An Investment Thesis on a Microcap Coding and Marking Franchise Aditya Pandey Abstract. Control Print is a profitable, almost debt-free Indian manufacturer of coding and marking equipment with a market capitalisation of about ₹ 896 Cr. Its standalone business earns 20–25% EBITDA margins, but consolidated margins have fallen to 13–19% because of an overseas packaging unit. The shares trade at 23× trailing earnings and are down 24% over the year. This thesis argues that the market is capitalising the overseas drag and ignoring the core. Base-case value is about ₹ 700 per share (+25%) over 18–24 months, with a bear case of about ₹ 440 and a bull case of about ₹ 900. Prices are as of 23 October 2026; financials run to Q1 FY27. 1. Introduction and Investment Thesis Control Print is the only Indian company among the four players that control almost 80% of India’s coding and marking market, where it holds a 18–20% share according to the company’s investor presentation. A printer is sold once, but the installed base, now above 23,000 machines, keeps generating demand for inks, fluids and spares for years. This is a recurring-revenue model that the market appears to be undervaluing because of one loss-making division. The thesis rests on two claims. First, the domestic core is a 20–25% standalone EBITDA-margin business. Second, the group’s margin compression comes mainly from the Italian packaging unit (CP Italy, the V-Shapes platform), which management says accounts for almost all of the foreign losses. If that drag narrows, earnings can recover without any improvement in the core. 2. The Business Control Print makes industrial printers that mark batch codes, expiry dates and barcodes onto products and packaging. The business follows a razor-and-blade model: the printer is the initial sale, and inks, fluids, cartridges, spares and service recur for as long as the machine runs. The company sold about 3,000 printers in FY26 (3,064 units). It is the only coding and marking company manufacturing in India, according to Crisil as cited on Screener, with plants at Nalagarh and Guwahati and a service network across more than 1,700 towns. – Growth. Standalone operating revenue was ₹ 446 Cr in FY26, up 16% from ₹ 385 Cr, a 17% CAGR over FY21–26 (company disclosure). Management guides to 10–15% growth in the core business this year. – Pricing. Standalone gross margin was 60.5% in Q4 FY26 (56.6% a year earlier) and 57.7% in Q1 FY27, up 122 basis points year on year, helped by price increases and a lower cost-of-goods ratio. – Cash generation. Operating cash flow was about ₹ 50 Cr in each of FY24, FY25 and FY26. Borrowings are ₹ 7 Cr against ₹ 41 Cr of investments, and the FY26 dividend was ₹ 10 per share (37% payout). 3. Why the Stock Appears Mispriced Consolidated sales rose 34% between FY24 and FY26, from ₹ 359 Cr to ₹ 482 Cr, but pre-tax profit was flat at about ₹ 73 Cr, as operating margin fell from 24% to 18%. Two effects account for much of this gap. 3.1 The core is more profitable than the group. Standalone EBITDA margin was 25.3% in Q4 FY26, against 18.8% on a consolidated basis. In Q1 FY27 the figures were 20.2% and 13.2%. Using the standalone operating revenue and consolidated operating profit for those quarters, the implied EBITDA gap is about ₹ 7.6 Cr in Q4 FY26 and ₹ 5.8 Cr in Q1 FY27 (author’s calculation). Management attributes the losses almost entirely to the Italian packaging business, not to Markprint (Netherlands) or Codeology. It describes the weak Q1 FY27 as the result of geopolitical disruption, volatile polymer prices and weak demand, and calls these factors temporary. 3.2 The tax rate appears to penalise the group. Management puts the consolidated effective tax rate close to 40%, compared with a statutory rate of about 25%. This suggests that foreign losses provide no relief against Indian profits. This is the author’s inference and should be confirmed from the tax note in the annual report. Reported EPS of ₹ 24 therefore understates earning power, while FY25 profit of ₹ 100 Cr was inflated by a one-off tax credit (Q4 FY25 effective tax rate of −213%). Trailing P/E is unreliable in both directions. 3.3 Value of the drag. At roughly 10× EV/EBITDA, an annual gap of ₹ 25–30 Cr is worth ₹ 250–300 Cr, or about 30% of the current market capitalisation of ₹ 896 Cr. 4. Valuation At ₹ 560, the shares trade at 23× trailing EPS of ₹ 24.4, about 2.0× book value of ₹ 283, and roughly 10× EV/EBITDA. Enterprise value is about ₹ 862 Cr, calculated as market capitalisation plus ₹ 7 Cr of borrowings less ₹ 41 Cr of investments; cash is not itemised separately. Third-party screeners (MoneyWorks4Me and Tijori Finance) report current multiples below the stock’s own three- to five-year history. Free cash flow is only ₹ 23 Cr in FY26 (a 2.6% yield), so this is a margin-recovery case rather than an asset-value case. The scenarios below are the author’s assumptions over 18–24 months on 1.6 crore shares and are illustrative, not forecasts. 2 Table 1. Valuation scenarios (author’s calculations) Scenario Key assumption PBT Tax EPS ( ₹ ) P/E Value ( ₹ ) vs ₹ 560 Bear Overseas losses persist; core margin near 20% ₹ 65 Cr 40% 24.4 18× 438 −22% Base Core grows 10–12%; standalone–consolidated gap halves ₹ 80 Cr 30% 35.0 20× 700 +25% Bull Packaging reaches break-even or is exited (≈ ₹ 25 Cr drag removed) ₹ 90 Cr 27% 41.1 22× 903 +61% The payoff is asymmetric: roughly −22% in the bear case against +25% to +61% in the base and bull cases, plus a 1.8% dividend while waiting. The bull case assumes a 22× multiple, slightly below the current trailing 23×, so it does not depend on a re-rating. 5. Catalysts and Milestones Table 2. Catalysts (company guidance and author’s expectations) Date Event Confirmation sought 28 Oct 2026 Q2 FY27 results and earnings call Standalone EBITDA margin above 22%; core growth within the 10–15% guidance; consolidated margin above Q1’s 13.2% H2 FY27 Decision on CP Italy (V-Shapes) Break-even plan, restructuring or exit, with no new capital before milestones are met FY27 UAE subsidiary (set up January 2025) Break-even, as management guided for FY 2026/27 May 2027 FY27 annual results Effective tax rate falling toward 30% as foreign losses narrow Ongoing Track-and-trace for pharmaceuticals Pilots converting to orders; division at break-even per management 6. Risks and Falsification Criteria – Capital allocation. Management’s Q4 FY26 commentary points to operational and quality-control problems at CP Italy. On the Q1 call it said it would not raise investment in other businesses or fund underperformers without a path to improvement. This commitment needs to be tested. – Working capital. Inventory days rose to 271 in FY26 from 224 in FY25, and the cash conversion cycle is 283 days. Other assets grew by ₹ 70 Cr in the year, and ROCE fell from 24% in FY24 to 16%. – Core slowdown. Standalone operating revenue grew only about 4% in Q1 FY27, and consolidated PBT fell 45% year on year, from ₹ 17.9 Cr to ₹ 9.8 Cr. If the weakness is not temporary, the base case fails. – Competition and costs. Polymer-linked ink costs and exchange rates affect margins. The other three leading players hold about 60% of the market between them. – Liquidity and governance. Institutional holdings are about 3% (FIIs 2.8%, DIIs close to zero), so exits could be slow. Promoter pledge and related-party disclosures have not yet been verified. Falsification criteria. The thesis is wrong if (1) standalone EBITDA margin stays below 18% for two consecutive quarters, indicating erosion in the core; (2) new capital goes into overseas packaging without a break-even date; (3) inventory days exceed 300 without a matching increase in sales; or (4) the tax rate stays near 40% even as overseas losses narrow, which would mean the tax explanation in section 3.2 is incomplete. 7. Method and Sources Financial ratios, cash flows and shareholding data were taken from Screener.in (consolidated, accessed 23 October 2026). These were checked against the company’s Q4 FY26 and Q1 FY27 earnings calls, investor presentations and third-party summaries. Revenue and margins agree across sources (FY26 operating revenue of ₹ 482 Cr; Q4 FY26 consolidated EBITDA margin of 18.8%). Market capitalisation varied from ₹ 896 to ₹ 948 Cr with the share price between 21 and 23 October. ROCE varies from 16% to 18% by provider definition; this thesis uses Screener’s consolidated figure of 16%. Enterprise value, the EBITDA gap and the scenario values are the author’s calculations. Items still to be verified are the FY26 annual report tax note, CP Italy segment figures, and promoter pledge and related-party disclosures. References Control Print Limited (2026) Transcript of earnings conference call, 21 May 2026 (Q4 and FY26) . Available at: https://controlprint.com (Accessed: 23 October 2026). Control Print Limited (2026) Q1 FY27 investor presentation , as reported by Investing.com (Accessed: 23 October 2026). Screener.in (2026) Control Print Ltd: consolidated financials and ratios . Available at: https://www.screener.in/company/CONTROLPR/consolidated/ (Accessed: 23 October 2026). Quartr (2026) Control Print Limited Q1 26/27 earnings summary . Available at: https://quartr.com (Accessed: 23 October 2026). MarketsMOJO (2026) Control Print Q4 FY26: profit volatility masks underlying strength . Available at: https://www.marketsmojo.com (Accessed: 23 October 2026). Tickertape (2026) Control Print Ltd (CONTROLPR) share price and market capitalisation . Available at: https://www.tickertape.in (Accessed: 23 October 2026).